Cleared Traditional

K092736 - EUROIMMUN ANTI-M2-3E ELISA (IGG)

K092736 is an FDA 510(k) clearance for EUROIMMUN ANTI-M2-3E ELISA (IGG), manufactured by Euroimmun Us, Inc.. The device is a Class 2 Immunology device with product code DBM cleared through the Traditional 510(k) pathway after a 363-day FDA review.

K092736 · Euroimmun Us, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2010
Decision
363d
Days
Class 2
Risk

K092736 is an FDA 510(k) clearance for the EUROIMMUN ANTI-M2-3E ELISA (IGG). Classified as Antimitochondrial Antibody, Indirect Immunofluorescent, Antigen, Control (product code DBM), Class II - Special Controls.

Submitted by Euroimmun Us, Inc. (Morristown, US). The FDA issued a Cleared decision on September 2, 2010 after a review of 363 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5090 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Immunology review framework, consistent with the majority of Class II 510(k) submissions.

View all Euroimmun Us, Inc. devices

FDA 510(k) Submission Details - K092736

510(k) Number K092736 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 04, 2009
Decision Date September 02, 2010
Days to Decision 363 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
258d slower than avg
Panel avg: 105d · This submission: 363d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DBM Device Classification - Class 2, Special Controls

Product Code DBM Antimitochondrial Antibody, Indirect Immunofluorescent, Antigen, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5090
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - DBM Antimitochondrial Antibody, Indirect Immunofluorescent, Antigen, Control

All 18
Devices cleared under the same product code (DBM) and FDA review panel - the closest regulatory comparables to K092736.
QUANTA Flash M2 (MIT3), QUANTA Flash M2 (MIT3) Calibrators, QUANTA Flash M2 (MIT3) Controls
K163525 · Inova Diagnostics, Inc. · Sep 2017
ImmuLisa Enhanced AMA IgG Antibody ELISA
K163133 · Immco Diagnostics, Inc. · Aug 2017
ELIA M2
K141375 · Phadia US, Inc. · Feb 2015
QUANTA LITE M2 EP (MIT3) ELISA
K052262 · Inova Diagnostics, Inc. · Oct 2005
BINDAZYME ANTI-MITOCHONDRIA M2 IGGAM EIA KIT
K030238 · The Binding Site, Ltd. · Mar 2003
ENZYMATIC MITOCHONDRIAL ANTIBODY (M2) REAGENT
K982121 · Trace Scientific , Ltd. · Sep 1998